Development↦Quality and Risk↦Study Risk Management↦Risk Identification
What is it? Why is it important?
In order to ensure the safety of study participants and the quality of study data, the SP-INV identifies risks related to study processes and data handling.
Risk identification is based on:
- System level: informatics, SOPs, infrastructure, laboratory, available work space, resources such as time and personnel, etc.
- Study level: study design, target population, data collection, Informed Consent process, type and complexity of the intervention (e.g. randomisation, double blind)
Based on risk identification the SP-INV implements a risk-based QMS. The scope of the risk-based QMS is based on the evaluation of the study`s risk management, which includes to:
- Evaluate risks on their likelihood of occurrence, ability to be detected, and potential risk impact
- Prioritise risks, and define risk control-measures in proportion to their estimated risk significance (e.g. potential impact on primary- or secondary endpoints)
More
When writing the study protocol, an estimation of potential study risks and their risk control-measures are defined. During study conduct the management and adaptation of study risks might become necessary. Consequently, risk identification and managment (evaluation & prioritisation, definition of risk control-measures) is a continuous process, starting at the time of protocol writing and only ends upon study completion.
Newly identified risks during study set-up, development and conduct might potentially necessitate a protocol amendment.
What do I need to do?
As a SP-INV you are responsible for the risk identification and management of your study such as to:
- Identify your study risks and ask yourself:
- What can go wrong in my study?
- What could affect patient rights, safety, and well-being?
- What could jeopardise data quality and consequently the integrity and credibility of my study results?
- Document all identified risks and their management in the RAF
- Implement a risk-based QMS with the aim to support the risk identification and management of your study. Include quality assurance and quality control aspects
As a SP-INV or Site-INV:
- Communicate and train staff on the risk management of the study
- Regularly review risk control measures in order to test its ongoing efficacy
- Document ongoing and newly identified risk occurrences, their implemented risk control-measures, including potential deviations and improvement procedures
More
Use ‘lessons learned’ from previous studies. Previous risk experience can facilitate the risk identification of a planned study.
Examples of study risks or what can go wrong:
- Safety: non-compliant processes in the assessment and documentation of adverse events, SAE, SUSAR
- Data protection: participant data becomes accessible to non-study staff
- Participant right: are not properly informed regarding study withdrawal or signing of ICF
- Data quality: data incomplete, unusable for final analysis
- Analysis: statistical method(s) is not applicable or inappropriate for data analysis
- Design: study feasibility is questionable resulting in poor compliance and incomplete dataset
- Biological material: lack of standardised processes for sample retrieval, handling and storage
- IMP/IMD: lack of optimal storage conditions and regulated access control
Where can I get help?
Your local Research Support Centre↧ can assist you with experienced staff regarding this topic
Basel, Departement Klinische Forschung (DKF), dkf.unibas.ch
Lugano, Clinical Trials Unit (CTU-EOC), ctueoc.ch
Bern, Department of Clinical Research (DCR), dcr.unibe.ch
Geneva, Clinical Research Center (CRC), crc.hug.ch
Lausanne, Clinical Research Center (CRC), chuv.ch
St. Gallen, Clinical Trials Unit (CTU), h-och.ch
Zürich, Clinical Trials Center (CTC), usz.ch
References
ICH GCP E6(R2) – see in particular guidelines
- 5.0 Quality management
- 5.0.2 Risk identification
ISO 31000 (access liable to costs) – see in particular section
- Risk management: Principles and guidelines